

1 **Definition of virological endpoints improving the design of HIV cure**
2 **strategies using analytical antiretroviral treatment interruption**

3

4

5 Marie Alexandre^{1,2‡}, Mélanie Prague^{1,2‡}, Edouard Lhomme^{1,2,5}, Jean-Daniel Lelievre^{2,3},
6 Linda Wittkop^{1,2,5}, Laura Richert^{1,2,5}, Yves Lévy^{2,3,4}, Rodolphe Thiébaud^{1,2,5*}

7

8 ¹ University of Bordeaux, Department of Public Health, Inserm Bordeaux Population Health
9 Research Center, Inria SISTM, Bordeaux, France

10 ² Vaccine Research Institute, Créteil, France

11 ³ Inserm U955, Créteil, France

12 ⁴ AP-HP, Hôpital Henri-Mondor Albert-Chenevier, Service d'Immunologie Clinique et Maladies
13 Infectieuses, Créteil, France

14 ⁵ CHU Bordeaux, Department of Medical information, Bordeaux, France

15

16 * Corresponding author:

17 Pr Rodolphe Thiébaud

18 Univ. Bordeaux, Inserm BPH, Inria SISTM

19 146 Rue Leo Saignat, 33076 Bordeaux

20 Email: rodolphe.thiebaud@u-bordeaux.fr

21

22 ‡These authors contributed equally to this work.

23

24

25 Reference count: 33 (/40)

26

27

28 **Abstract**

29

30 **Background.** Analytical treatment interruption (ATI) is the gold standard in HIV research to
31 validate the ability of novel therapeutic strategies to long-term control viremia without
32 antiretroviral treatment (ART). Viral setpoint is commonly used as endpoint to evaluate their
33 efficacy. However, to mitigate higher viremia risk without ART, trials use short ATI phases and
34 strict virological ART re-start criteria, compromising the observation of the setpoint.

35 **Methods.** We analyzed viral dynamics in 235 HIV-infected participants from three trials,
36 examining various virological criteria during ATI phases. Time-related (e.g. time to rebound,
37 peak and setpoint) and VL magnitude-related criteria (peak, setpoint and time-averaged AUC
38 [nAUC]) were described. Spearman correlations were analyzed to identify surrogate
39 endpoints for setpoints. Additional correlation analyzes were performed to identify optimal
40 virological ART re-start criteria mitigating the risks of ART interruption and the evaluation of
41 viral control.

42 **Results.** Comparison of virological criteria between trials showed strong dependencies on ATI
43 design. Similar correlations were found across trials, with nAUC identified as the criterion
44 most strongly correlated with the setpoint, with correlations higher than 0.70. A threshold of
45 at least 100,000 copies/mL for two consecutive VL measurements is requested as virological
46 ART re-start criteria to keep strong correlations between the setpoint and nAUC.

47 **Conclusions.** Our results emphasize the benefits of an ATI phase longer than 12 weeks, with
48 regular monitoring, and a VL threshold of 100,000 copies/mL as virological ART re-start
49 criteria to limit the risk for patients while capturing enough information to keep nAUC as an
50 optimal proxy for the setpoint.

51 **Keywords.** Analytical treatment interruption, clinical trials, antiretroviral treatment, HIV cure,
52 viral rebound, virological endpoint.

53 **Introduction**

54 Treatment interruption, i.e., discontinuation of antiretroviral treatment (ART), has been used
55 in the evaluation of strategies aimed to save drug exposure (1–3). However, interruption of
56 ART is associated to a higher risk for clinical progression (4). Nevertheless, treatment
57 interruption remains the only means to evaluate therapeutic interventions such as
58 immunotherapies or therapeutic vaccines (5) aimed to control HIV replication without ART
59 (6–11).

60 While accepted in a context of clinical trials involving people living with HIV (PLWH) (12,13),
61 treatment interruption should be carefully monitored and several recommendations have
62 been proposed to limit potential risks, in terms of morbidity, mortality, disease progression,
63 HIV transmission, emergence of new drug-resistance, development of neurological or
64 cardiovascular disorders (14,15). These recommendations led to the development of clearly-
65 defined interruptions: Analytical treatment interruptions (ATI) (14). Therefore, it is of the
66 utmost importance to optimize the design of ATI trials to provide a maximum information
67 with a minimum risk exposure (16). Stringent ART re-start criteria upon viral rebound are
68 included in research protocols while virological endpoints to assess efficacy of experimental
69 strategies have been largely discussed (14,16–20). Two types of criteria are usually
70 considered in the definition of virological endpoints, each leading to a distinct design of the
71 ATI phase: the time to viral rebound and the setpoint, that is the relatively stable level of HIV
72 viral load (VL) after the rebound (14,21). When the outcome of interest is the time to viral
73 rebound, the threshold of VL for ART re-start is often set at a low level to limit risks (e.g. 1
74 000 copies/mL). Optimal designs have been recently proposed for studies using “time to viral
75 rebound” as endpoints (16). One drawback here could be the ART re-start at a low viral
76 rebound which impair the evaluation of viral replication control. On the other hand, studies
77 using “setpoint” as endpoint require longer treatment interruption periods with higher
78 thresholds for ART re-start, leading to a potential increased risk of HIV transmission and side
79 effects. Thus, while the “time to rebound” could be easily determined in ATI studies,
80 assessing the setpoint of viral replication, a proxy of the control of viral rebound, remains
81 challenging. Therefore, the need to define optimal designs of ATI phase for “setpoint”
82 studies, mitigating the risks related to treatment interruption and the evaluation of viral
83 control, is essential.

84 In the present study, we analyzed several virological parameters of the kinetics of viral
85 rebound following ATI in various clinical trials of immunotherapeutics in chronic PLWH. The
86 objective was to identify at earliest phase of ATI potential surrogate endpoints predictive of
87 viral setpoints. These results might have a practical impact on the design of future clinical
88 trials with ATI.

89 **Materials and Methods**

90 **Clinical trial data**

91 We considered individual data extracted from three distinct trials in PLWH including two
92 therapeutic vaccine trials and one testing an IL-2 immunotherapeutic strategy. All trials
93 comprised an ATI phase to evaluate the virological efficacy of these strategies in maintaining
94 low viral replication after ART interruption (**Figure 1**).

95 The VRI02 ANRS 149 LIGHT trial (22) (NCT01492985, and labelled LIGHT) was a multicenter,
96 double-blind, placebo-controlled, randomized, Phase II trial evaluating the safety,
97 immunogenicity and virological efficacy of a prime-boost vaccine strategy, using recombinant
98 DNA vaccine GTU-MultiHIV B as prime, and lipopeptide vaccine HIV-LIPO-5 as boost.

99 The ANRS/VRI DALIA trial (23–25) (NCT00796770, and labelled DALIA) was a single-center,
100 single arm Phase I trial evaluating the safety of a dendritic cell vaccine.

101 The ANRS 118 ILIADE trial (26) (NCT00071890, and labelled ILIADE) was a multicenter, open-
102 label, placebo-controlled, randomized Phase II/III trial evaluating the efficacy of IL-2
103 immunotherapy to extend the period of time off ART, defined by three cycles of
104 subcutaneous injections of recombinant IL-2.

105 In LIGHT, 103 ART-treated HIV-infected patients were randomized in a 2:1 ratio to receive
106 their ART in combination with either an active vaccine or placebo. From week 36 to 48,
107 patients interrupted their ART and were regularly monitored with immunological (CD4+ and
108 CD8+ T cell counts) and VL measurements performed every 2 weeks (**Figure 1A**). The primary
109 virological endpoint studied was the maximum observed VL (in log₁₀ copies/mL) during ATI
110 phase.

111 In DALIA, 19 ART-treated HIV-infected patients were included who interrupted ART for 24
112 weeks, from week 24 to 48, and were monitored every 1 to 4 weeks (**Figure 1C**). No
113 virological endpoint was evaluated in this study.

114 Finally, ILIADE enrolled 148 ART-treated HIV-infected patients randomized in a 1:1 ratio to
115 receive ART either in combination with IL-2 therapy or alone. From week 24 to 72, ART was

116 interrupted and CD4+, CD8+T cells counts and VL were collected every 8 weeks (**Figure 1B**).
117 No virological endpoint was considered in ILIADE.

118 The reader can refer to **Figure 1** for the list of criteria leading to ART re-start before the end
119 of the protocol-defined ATI phase.

120 **Ethics statement**

121 The protocol of LIGHT study was approved by the ethics committee of Ile de France 5 (Paris-
122 Saint-Antoine) and authorized by the French regulatory authority (ANSM). The DALIA study
123 was sponsored by the Baylor Institute for Immunology Research and the Agence Nationale
124 de Recherches sur le SIDA et les hepatites (INSERM ANRS), and the protocol was approved by
125 the IRB of Baylor Research Institute (BRI). The protocol of ILIADE study was approved by the
126 ethics committee of the Hospital Henri Mondor and the National Institute of Allergy and
127 Infectious Diseases (NIAID). All participants provided written informed consent before
128 participation.

129 **Definition of virological criteria**

130 Virological data of the trials described above were analyzed in the present study, and a total
131 of eight criteria summarizing the dynamics of viral rebound during ATI were considered. To
132 account for the differences of design of ATI phases between the three trials (e.g., ATI phase
133 duration or sampling frequencies, virological criteria were divided into two categories: (1)
134 fixed criteria if they were principally related to the magnitude of VL and, (2) temporal criteria
135 if they corresponded to time-related outcomes.

136 The three fixed criteria included in this analysis were (1) peak VL, (2) setpoint and, (3) time-
137 averaged area under the curve (AUC) (i.e., AUC divided by the duration of ATI phase, labelled
138 nAUC). A normalized version of AUC was used to adjust for ATI duration and to be
139 comparable between patients. In the absence of a formal definition of the setpoint in the
140 literature, the steady state of VL reached after the peak VL was defined as the mean of
141 observations included in a sliding window of height $0.5 \log_{10}$ copies/mL, with a width of at
142 least 4 weeks and including at least two VL values (17). Moreover, the assumption that the
143 setpoint was correctly measurable in the different trials was made.

144 The temporal criteria were (1) time to rebound (TTR), (2) slope of viral rebound, (3) time to
145 peak VL, (4) time to setpoint, (5) time to distinct VL thresholds (i.e., 200, 1 000, 10 000 and

146 100 000 copies/mL). The reader can refer to **Table 1** and **Figure 2A** for a full definition of
147 these criteria

148 **Identification of the optimal virological criterion to be used as primary endpoint**

149 We sought to identify optimal criterion summarizing viral dynamics that could be used as
150 proxy for the setpoint, based on the following characteristics: highly associated with the
151 setpoint, and whose observation is less impacted by the duration of ATI phase.

152 Individual viral dynamics can be impacted by both the effect of the intervention and the
153 design of ATI phase. In each trial, the design of ATI being comparable between the two
154 groups of treatment, we first performed a descriptive analysis and a comparison of the two
155 groups at each time point to identify potential differences of dynamics, induced by treatment
156 effect, that could impact the values of virological criteria. As no statistical differences were
157 identified between groups, whether in LIGHT or ILIADE and whatever the time point, the two
158 groups were pooled together in each trial to increase statistical power. The following
159 analyses were then performed at trial level (i.e., LIGHT Vs ILIADE Vs DALIA). Secondly, once
160 the eleven aforementioned virological criteria estimated for each individual, a descriptive
161 and comparison analysis between trials were performed to analyze how ATI designs
162 impacted their values. Finally, Spearman correlations were evaluated between criteria and
163 compared between trials to (1) see how ATI designs impact correlation patterns, and (2)
164 identify criterion the most associated to the setpoint.

165 In this analysis, patients were excluded if they fulfilled one of the following criteria: ATI not
166 initiated, detectable VL at the time of ART interruption (condition for ATI initiation),
167 therapeutic strategy not received (e.g., at least one IL-2 dose requested in ILIADE). Moreover,
168 only the first 48 weeks of ATI (i.e., until the primary outcome at week 72, see Figure 1B) were
169 included in ILIADE, to limit heterogeneity among trials.

170 **Assessment of the choice of virological restart ART criteria on the evaluation** 171 **of the virological endpoint**

172 To limit the risks for participants during ATI phase, ART re-start criteria are defined in
173 protocols. These criteria define conditions under which it is vital for a patient to re-start ART
174 before the end of ATI phase. While the patient remains in the trial and is still frequently
175 monitored after ART re-start to ensure its safety and to contribute to other endpoints, this

176 one does not fulfill conditions to contribute to virological endpoint. Consequently, censoring
177 of follow-up is considered due to strategy discontinuation and virological measurements
178 collected from that point are treated as monotonic missingness (once missing, always
179 missing subsequently) for the evaluation of virological criteria. Although ART re-start criteria
180 can have a strong impact on primary outcomes and, by extension, on the evaluation of
181 vaccine efficacy, no real consensus has been reached about their definition (14). In this work,
182 we focused on virological ART re-start criteria defined as VL threshold above which patients
183 have to re-start ART for their safety, named VL upper-threshold thereafter. As shown in
184 **Figure 2B**, censored follow-up, resulting from the use of VL upper-threshold, required the
185 study of right-censored viral dynamics.

186 We re-analyzed the three trials by investigating the impact of VL upper-thresholds on the
187 association between the setpoint and nAUC. Three commonly considered VL upper-
188 thresholds were investigated: (1) 10 000 copies/mL, (2) 50 000 copies/mL, and (3) 100 000
189 copies/mL. To this end, Spearman correlations were studied between the setpoint, estimated
190 on complete data (i.e., not impacted by VL upper-threshold), and the nAUC calculated on
191 right-censored viral dynamics, labelled right-censored nAUC (**Figure 2B**). Moreover, we
192 investigated the need for a confirmation measure before any ART restart. To this end,
193 correlations between the setpoint and the nAUC were evaluated considering censoring of
194 follow-up either 1) as soon as VL upper-threshold has been exceeded for one viral measure
195 (i.e., without confirmation measure), or 2) once VL upper-threshold has been exceed for two
196 consecutive viral measures (i.e., with confirmation measure).

197 **Statistical analysis**

198 All analyses were performed in R (version 4.2.1). Continuous variables were expressed in
199 median (interquartile [IQR]), and discrete variables in absolute number and percentage. The
200 Student t-test was used to compare VL measurements between groups. The non-parametric
201 Mann-Whitney U and Kruskal-Wallis tests were used to perform pairwise comparisons and
202 multiple group comparisons of virological criteria, respectively. The associations between
203 virological criteria in each trial were evaluated using Spearman correlations. Statistical
204 significance was defined as a p-value lower than 0.05, after Benjamini and Hochberg false
205 discovery rate-adjustment (27) for multiple testing.

206 **Results**

207 **Population**

208 A total of 235 patients, out of the 270 enrolled in the three trials, were included in the
209 present study: 87 in LIGHT (n=31 in placebo group and n=56 in vaccine group), 129 in ILIADE
210 (n=57 in control group and n=72 in IL-2 group) and 19 in DALIA (**Figure S1**).

211 **Description of virological measurements**

212 Viral rebound dynamics for the three trials are shown in **Figure 3**, and distributions of VL
213 measured at each sampling time point during ATI phase are summarized in **Table S1**. The
214 median length of follow-up before ART re-start ranged from 12 to 48 weeks, with a median
215 number of VL measurements from 6 to 11 (**Table 2**). The percentages of patients prematurely
216 reinitiating their ART before the end of ATI phase were equal to 21 % in LIGHT (23% for
217 Placebo and 20% for vaccinated), 26% in ILIADE (35% for Control and 19% for IL-2), and 16%
218 in DALIA.

219 Comparisons, at the different time of measurements, between VL values collected in the
220 experimental and the control group highlighted similar viral, whether in LIGHT (p-values >
221 0.43) or in ILIADE (p-values > 0.53) (see **Table S1**). Groups were then pooled in each trial to
222 increase the statistical power. As shown in **Figure 4**, no significant difference was observed
223 between the different trials from week 8 (p-value > 0.28). However, viral dynamics differed
224 across trials during the earliest phase of ATI. Mean VL measured in DALIA were significantly
225 lower than in LIGHT at weeks 2 and 4 (2.05 vs 2.49 log₁₀ copies/mL at week 2, p-value=0.04;
226 3.26 vs 4.12 log₁₀ copies/mL at week 4, p-value=0.04).

227 Despite the absence of strong differences in the dynamics of viral rebound between trials,
228 the duration of ATI phase, sampling frequencies and intervals differ between trials, and
229 consequently can impact values of virological criteria.

230 **Assessment of different virological criteria definitions**

231 The virological criteria describing dynamics of viral rebound calculated in the different groups
232 are summarized in **Table 3**. No statistical differences were found between groups in LIGHT
233 (Placebo vs Vaccine) and ILIADE (Control vs IL-2), allowing an analysis at trial level in the
234 following results (**Figure 5**).

235 *Fixed criteria*

236 No statistical differences of setpoints were observed between trials with mean values ranged
237 from 4.23 in DALIA to 4.42 log₁₀ copies/mL in LIGHT (p-value=0.39) (**Figure 5B**). This result
238 was in accordance with the absence of significant differences of VL measurements beyond
239 week 4. Despite this homogeneity among trials, a lower percentage of patients reached the
240 setpoint during ATI in LIGHT (54%) compared to both DALIA (95%) and ILIADE (86%). This
241 difference can be explained by the shorter ATI phase of only 12 weeks in LIGHT, making its
242 observation more difficult.

243 Both the peak VL and the nAUC were significantly different between LIGHT and ILIADE,
244 whereas no differences were observed between DALIA and LIGHT, DALIA and ILIADE. As
245 shown in **Figure 5A** and **Figure 5C**, the mean peak VL was significantly higher in LIGHT than in
246 ILIADE (+ 6%, p-value <0.001), while the mean nAUC was significantly lower in LIGHT than in
247 ILIADE (- 8%, p-value <0.01). Though not a direct time-dependent criteria, the lower peak VL
248 in ILIADE can be explained by its study design: the longer the time-interval between two VL
249 measurements (every 8 weeks in ILIADE instead of 2 weeks in LIGHT), the higher the
250 probability to miss the peak and capture a measure in the decreasing dynamic following the
251 peak (see **Figure S3** for an illustration).

252 *Time-dependent criteria*

253 The analysis of time-dependent criteria highlighted their strong dependence on study design,
254 i.e. ATI duration and sampling intervals. As shown in **Table 3** and **Figure 5 D-F**, with VL
255 measurements collected every 8 weeks, ILIADE's patients showed significantly different
256 results than those included in LIGHT and DALIA. In particular, they were characterized by a
257 significantly higher mean TTR and time to setpoint (TTR: 8.64 vs 3.04 and 4.47 weeks,
258 respectively, p-values < 0.001 ; time to setpoint: 15.9 vs 6.43 and 10.9 weeks, respectively, p-
259 values <0.001). In contrast, a significantly lower mean slope of rebound was observed in
260 ILIADE than in both LIGHT and DALIA (-69% and -62%, respectively, p-value <0.0001). These
261 variations mostly result from the higher TTR. Except for barely significant lower mean time to
262 setpoint between LIGHT and DALIA (6.43 vs 10.9 weeks, p-value < 0.05), explained by the
263 difference of ATI duration, similar temporal endpoints were observed in these two trials.

264 **Analysis of correlations between virological criteria.**

265 To identify virological criteria summarizing viral rebound and highly associated with the
266 setpoint, we performed correlation analysis between the virological criteria. **Figure 6**
267 displayed Spearman correlations between the five virological criteria the most used obtained
268 in the three trials (see **Figure S4** for correlations between the eleven virological criteria
269 defined in this analysis, and **Figure S5** for Pearson correlations and scatter plots). Similar
270 patterns of correlations were obtained between the different trials. First, the absence of
271 significant correlations between the TTR and the setpoint, the two virological endpoints the
272 most widely recommended to assess vaccine efficacy in HIV therapeutic clinical trials (14).
273 Second, we identified strong significant positive correlations between the setpoint and both
274 the peak VL and the nAUC (p-values < 0.001), with higher correlation coefficients for the
275 nAUC (0.70 vs 0.61 in LIGHT, 0.90 for both in ILIADE, and 0.75 vs 0.73 in DALIA). The
276 correlations between TTR and other endpoints were less consistent across trials. For
277 instance, a negative correlation between the TTR and the nAUC was found in LIGHT (-0.57, p-
278 value <0.0001) but not in DALIA and ILIADE.

279 These results allowed to identify the nAUC as the virological criteria the most strongly
280 correlated with the setpoint, and which can be evaluated regardless the design of the ATI
281 phase. However, it was worth noting that the strongest correlations between these two
282 criteria were observed in ILIADE rather than in LIGHT, indicating that this association seems
283 influenced by the duration of ATI phase.

284 **Virological restart criteria impact the association between the setpoint and the** 285 **nAUC.**

286 We assessed the impact of ART re-start criteria, defined as VL upper-threshold (see **Figure**
287 **2B**), on the correlation between the setpoint and the nAUC. **Figure 7** illustrated the
288 Spearman correlations between the setpoint and the right-censored nAUC for different
289 values of the VL upper-threshold (whether for discrete values in **Figure 7A** or continuous
290 values in **Figures 7B-D**), with or without considering a confirmation measure before
291 censoring follow-up. In most cases, the higher the VL upper-threshold, the more significant
292 and stronger the correlation coefficient. Moreover, results obtained in both LIGHT and DALIA
293 highlighted the benefit of considering a confirmation measure to retrieve the significance of
294 correlations. While no significant correlations were identified in these two trials in absence

295 of confirmation measure, positive significant correlations were identified when an additional
296 VL measure was considered with a VL threshold of 100 000 cp/mL. The use of a low
297 threshold to censure data can lead to non-conclusive results (non-significant and weak
298 correlation coefficients), or even lead to wrong conclusion about vaccine efficacy. As
299 example, an inversion of the sign of correlations was observed for intermediate VL upper-
300 threshold without confirmation measure, between 3.5 and 4.8 \log_{10} copies/mL in DALIA and
301 between 4.0 and 4.5 \log_{10} copies/mL in LIGHT. The use of a VL upper-threshold of at least
302 100 000 copies/mL with a confirmation measure allowed to retrieve at least 50% of the
303 magnitude of the correlation between the setpoint and nAUC estimated on complete data
304 (LIGHT: 50%, ILIADE: 94%, DALIA: 83%).

305 Discussion

306 This analysis of virological criteria in three different ATI clinical trials showed that the design
307 of ATI phase and the definition of the virological endpoints are crucial for the evaluation of
308 HIV cure strategies. When comparing the different virological criteria between the ATI trials,
309 we found that especially the results of time-dependent virological criteria varied according to
310 the design of ATI phase, i.e. ATI duration, sampling frequencies and intervals between viral
311 load measurements. Our study identified the nAUC as the virological criteria the most
312 strongly correlated with the setpoint. It has to be noted that, unlike the setpoint, the nAUC
313 can be observed regardless of the design of ATI phase. Furthermore, we showed that the use
314 of a too conservative threshold for virological ART re-start criterion can induce an increasing
315 risk of missing important effects of the immune intervention on viral control. However, the
316 use of a high value, i.e. 100 000 copies/mL reinforces the value of nAUC as a valid proxy of
317 the setpoint. In particular, if the interest is in the post-replication control of infection,
318 through the so-called setpoint studies (16), we showed that the nAUC is a valuable endpoint
319 even in case of censored follow-up (28). Our results of correlations between virological
320 criteria were consistent with those reported in other trials (17). The absence of correlation
321 between time to rebound and setpoint has already been reported in other studies such as in
322 the pooled analysis of 6 ACTG trials (19). Biologically, this could be explained by the fact that
323 the initiation of the viral replication and the control of it afterwards are driven by different
324 biological mechanisms. A recall T cell response stimulated by the start of the viral replication
325 is potentially responsible for post-replication control (3,29). Hence, the pre-ART viral load is
326 more correlated to the viral setpoint (19) than the time to rebound. Consequently, this
327 absence of correlation emphasizes the necessity of choosing the most accurate and relevant
328 primary endpoints that is in accordance with the objective of the trial. In the present work, it
329 is also interesting to point out that the viral slope is also weakly correlated with the viral
330 setpoint, suggesting that the secondary immune response is playing a bigger role on the
331 control of viral replication after the peak as it is observed during primary infection.

332 This study is based on three clinical trials and thus the generalizability of our result may be
333 limited. However, the information brought by real observed data from existing clinical trials
334 helps to go beyond simulations (16) and the results were consistent with results reported in
335 other additional trials (17,19). When the intervention and its expected impact is based on

336 other mechanism than active immune control of viral replication such as passive
337 immunization through neutralizing antibodies (Sneller et al. Science Trans Med 2019) then
338 other endpoints and designs should be considered.

339 The statistical requirement that ART should not be re-initiated before confirmed viral load of
340 more than 100 000 copies/mL is in agreement with what is recommended when the interest
341 is in the viral setpoint (14). This does not preclude to consider all additional criteria (clinical
342 and CD4 count) for patients' safety. Specific statistical approaches have been developed to
343 take into account incomplete information in such context (28).

344 Beyond statistical and clinical considerations, patient's perception should be taken into
345 account and recent studies have shown the good acceptability of ATI trials (12,13,30) as long
346 as severe side effects are avoided (31). According to these studies, a part of the respondents
347 would not accept any sustained period of viremia (35% in (32)). This would potentially
348 restrict the inclusion rate in the trials. Also, the preferred frequency of biological
349 measurements and clinical monitoring during ATI was monthly (32). Biotechnological
350 improvements making measurements at home feasible could help coping with this patient's
351 preference (33).

352 **Key recommendations for future HIV therapeutic trials with ATI evaluating the**
353 **ability of a treatment to control viral replication in the absence of ART**

354 Results provided by this work allowed us to make some recommendations. First, the time-
355 averaged area under the viral rebound curve during the ATI phase (nAUC here) has been
356 shown to be the optimal virological criterion to use as proxy to the setpoint and
357 consequently as primary virological endpoint. Secondly, the optimal design of ATI phase
358 allowing a good balance between minimization of the risk for patients and the maximization
359 of the capacity to evaluate the effect of intervention on viral dynamics includes (1) a duration
360 of the ATI phase of more than 12 weeks and no longer than 24 weeks to ensure patients
361 safety, (2) regular monitoring during the early phase of the viral rebound dynamics, with viral
362 load measurements every 1 to 2 weeks until reaching the setpoint (i.e., around week 12),
363 and (3) viral load measurements every 2 to 4 weeks thereafter. Finally, the use of the VL
364 upper-threshold of 100 000 copies/mL as virological ART re-start criteria appears as the best
365 trade-off limit the risk for patients and capture enough information to keep nAUC as a good

366 proxy of the setpoint. These results and proposals could help to optimize the design of
367 clinical trials testing HIV cure strategies.

368

369 **Contributions**

370 Y.L., M.P., and R.T. conceptualized the study. M.A. accessed and verified data, and conducted
371 the formal analysis. M.P. and R.T. supervised the analysis. All authors contributed to data
372 interpretation. M.A created the first draft of the figures, and M.A. and R.T. wrote the first
373 draft of the manuscript. All authors critically revised and edited the manuscript and
374 approved the final version for submission.

375

376 **Funding**

377 This work was supported by the Investissements d’Avenir program managed by the ANR
378 under reference ANR-10-LABX-77-01 (VRI - Vaccine Research Institute) and by the European
379 Union’s Horizon 2020 research and innovation program under grant agreement No. 681032
380 (EHVA).

381

382 **Data availability**

383 The data that support the findings of this study are available from the corresponding author,
384 R.T, upon reasonable request.

385

386 **Conflicts of interests**

387 The authors declare no competing interests.

388

389

390 **Legend of Figures**

391 **Figure 1 – Study designs of HIV therapeutic vaccine trials. (A) LIGHT trial.** Participants received a
392 prime-boost vaccine strategy, using recombinant DNA vaccine GTU-MultiHIV B or placebo as prime (3
393 doses at weeks 0, 4 and 12), and lipopeptide vaccine HIV-LIPO-5 or placebo as boost (2 doses at
394 weeks 20 and 24). **(B) ILIADE trial.** Participants an IL-2 immunotherapy, defined by three cycles of

395 subcutaneous injections of recombinant IL-2 (2 injections of 6×10^6 international units (IU) per day for
396 5 days, at weeks 0, 8 and 16), or placebo. **(C) DALIA trial.** Participants received 4 doses of a dendritic
397 cell vaccine, at weeks 0, 4, 8 and 12 weeks. **(A-C)** In the three trials, patient could prematurely re-
398 start ART during the protocol-defined ATI phase if they met the following criteria: (1) wish of patients
399 or of their doctors, (2) CD4+ T-cell count dropped below 350 cells/ μ L at two consecutive
400 measurements 2-weeks apart, and (3) occurrence of an opportunistic infection or a serious non-AIDS
401 defining event. In DALIA, a drop of CD4+ T-cell count below 25% of total lymphocytes for two
402 consecutive measurements was also considered. Analysis performed in this paper focused exclusively
403 on viral load data collected during ATI phase (i.e., free-of-ART phase). In ILIADE and DALIA, only data
404 collected from ART interruption to the time of primary endpoint (colored in orange, W72 and W48,
405 respectively) were considered.

406 **Figure 2 – Graphical representation of virological criteria analyzed in the study.** Black and white dots
407 represent detectable and undetectable viral load measurement collected during ATI phase,
408 respectively, and gray dots those collected after ART re-start. The horizontal gray dotted line
409 represent the limit of detection. **(A)** Virological criteria describing viral rebound dynamics. **(B)**
410 Virological restart ART criteria inducing strategy discontinuation and censoring of follow-up. Orange
411 dot shows the first viral load measure exceeding the VL upper-threshold represented by the
412 horizontal red dashed line (i.e., time at which viral dynamic is censored when no confirmation
413 measure is considered before ART re-start). Red dot shows the viral load measure at which viral
414 dynamic is censored when a confirmation measure is required before any ART resumption. Gray
415 crosses display viral load measures unobserved due to censoring of following after strategy
416 discontinuation.

417 Abbreviations: ART, antiretroviral treatment; TTR, time to rebound; TTsetpoint, time to setpoint;
418 TTPeak, time to VL Peak; AUC, area under the curve; VL, viral load.

419 **Figure 3 – Viral dynamics observed in the three trials in ATI phase.** **(A)** Viral dynamics observed
420 during 12-week ATI phase in LIGHT trial, with monitoring every 2 weeks. **(B)** Viral dynamics observed
421 during 48-week ATI period in ILIADE trial, with monitoring every 8 weeks. **(C)** Viral dynamics observed
422 during 36-week ATI period in DALIA trial, with monitoring every 1 to 4 weeks. **(A-C)** Thick and thin
423 lines represent the median and individual dynamics, respectively, and error bars represent
424 interquartile ranges. Solid and dashed lines correspond to dynamics in therapeutic and
425 control/placebo groups, respectively. Grey areas highlight limits of detection (i.e., 40 cp/mL for LIGHT,
426 and 50 cp/mL for ILIADE and DALIA). Red dotted vertical lines for represents the end of ATI phase
427 (week 12 in LIGHT and week 36 in DALIA).

428 **Figure 4 – Distribution of viral load measurements collected during ATI phase in the three trials at**
429 **common time points** (LIGHT in blue, ILIADE in green, and DALIA in pink). Brackets show significant p-
430 values after multiplicity adjustment: *: $p \leq 0.05$, **: $p \leq 0.01$, ***: $p \leq 0.001$, ****: $p \leq 0.0001$.

431 **Figure 5 – Distribution of different virological criteria within each trial.** Blue thick brackets below
432 boxplots and black thin brackets above boxplots show significant p-values of the multiple group
433 comparisons (Kruskal-Wallis test) and pairwise comparisons (Mann-Whitney U test), respectively.
434 Significant p-values after multiplicity adjustment: *: $p \leq 0.05$, **: $p \leq 0.01$, ***: $p \leq 0.001$, ****: $p \leq$
435 0.0001 . **(A)** Distribution of the peak VL, in \log_{10} cp/mL. **(B)** Distribution of the setpoint, in \log_{10} cp/mL.
436 **(C)** Distribution of the time-averaged AUC (nAUC), in \log_{10} cp/mL. **(D)** Distribution of the time to
437 rebound, in weeks. **(E)** Distribution of the slope of the viral rebound, in \log_{10} cp/mL/week. **(F)**
438 Distribution of the time to setpoint, in weeks. **(G)** Distribution of the time to peak of VL, in weeks. **(H)**
439 Time to 200 copies/mL of VL, in weeks. **(I)** Time to 1 000 copies/mL of VL, in weeks. **(J)** Time to 10 000
440 copies/mL of VL, in weeks. **(K)** Time to 100 000 copies/mL of VL, in weeks. Abbreviations: nAUC,
441 time-averaged area under the curve ; VL, viral load.

442 **Figure 6 – Heatmap of pairwise Spearman correlations between the five main virological criteria in**
443 **the three clinical studies.** **(A)** LIGHT clinical trial (n=87). **(B)** ILIADE clinical trial (n=129). **(C)** DALIA
444 clinical trial (n=19). **(A-C)** Correlations higher than 0.5 are colored in orange-red palette and
445 correlations lower than -0.5 in blue palette. P-values adjusted for multiplicity testing are indicated in
446 brackets: *: $p \leq 0.05$, **: $p \leq 0.01$, ***: $p \leq 0.001$, ****: $p \leq 0.0001$. Abbreviations: nAUC, time-
447 averaged area under the curve; TTR: time to rebound.

448 **Figure 7 – Spearman correlations between the setpoint and nAUC calculated on right-censored viral**
449 **dynamics according to VL upper-thresholds.** **(A)** Heatmap of Spearman correlations in each trial (y-
450 axis) between the setpoint and nAUC, whether with or without censoring of follow-up, and with or
451 without consideration of a confirmation measure before premature ART restart. Three commonly
452 used VL upper-thresholds are considered: 10 000 cp/mL, 50 000 cp/mL and 100 000 cp/mL.
453 Significant positive and negative correlations are highlighted in red and blue, respectively. **(B-D)**
454 Analysis of Spearman correlations between the setpoint estimated on complete virological data, and
455 the nAUC estimated on right-censored viral dynamics. The x-axis represents the VL upper-thresholds
456 above which censoring of follow-up was considered. The y-axis represents the value of the
457 correlation coefficient between the setpoint and the right-censored nAUC. Solid and dashed lines
458 represent the results with or without a confirmation measure in the calculation of the right-censored
459 nAUC, respectively. Yellow symbols (circles and triangles for with or without confirmation,
460 respectively) highlight significant correlations (adjusted p-value ≤ 0.05). The horizontal gray dotted

461 line represents the transition between positive and negative correlations. The horizontal red solid line
462 represents the value of the correlation coefficient between the setpoint and the nAUC estimated on
463 complete data. **(B)** LIGHT trial. **(C)** ILIADE trial. **(D)** DALIA trial.

464 References

- 465 1. Davey RTJ, Bhat N, Yoder C, Chun TW, Metcalf J, Dewar R, et al. HIV-1 and T cell dynamics after
466 interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained
467 viral suppression. 1999;6.
- 468 2. Ortiz GM, Wellons M, Brancato J, Vo HTT, Zinn RL, Clarkson DE, et al. Structured antiretroviral
469 treatment interruptions in chronically HIV-1-infected subjects. Proceedings of the National
470 Academy of Sciences. 6 nov 2001;98(23):13288-93.
- 471 3. Oxenius A, Price DA, Günthard HF, Dawson SJ, Fagard C, Perrin L, et al. Stimulation of HIV-specific
472 cellular immunity by structured treatment interruption fails to enhance viral control in chronic
473 HIV infection. Proceedings of the National Academy of Sciences. 15 oct 2002;99(21):13747-52.
- 474 4. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM,
475 Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. CD4+ count-guided interruption of
476 antiretroviral treatment. N Engl J Med. 30 nov 2006;355(22):2283-96.
- 477 5. Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MAWP, et al. Research priorities for an
478 HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat Med. déc
479 2021;27(12):2085-98.
- 480 6. Gunst JD, Højen JF, Pahus MH, Rosás-Umbert M, Stiksrud B, McMahon JH, et al. Impact of a TLR9
481 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN
482 trial. Nat Med. oct 2023;29(10):2547-58.
- 483 7. Julg B, Stephenson KE, Wagh K, Tan SC, Zash R, Walsh S, et al. Safety and antiviral activity of triple
484 combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical
485 trial. Nat Med. juin 2022;28(6):1288-96.
- 486 8. Lee MJ, Collins S, Babalis D, Johnson N, Falaschetti E, Prevost AT, et al. The RIO trial: rationale,
487 design, and the role of community involvement in a randomised placebo-controlled trial of
488 antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs)
489 in participants diagnosed with recent HIV infection—study protocol for a two-stage randomised
490 phase II trial. Trials. 5 avr 2022;23(1):263.
- 491 9. Sneller MC, Justement JS, Gittens KR, Petrone ME, Clarridge KE, Proschan MA, et al. A
492 randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals
493 who initiated antiretroviral therapy early in infection. 2017;11.
- 494 10. Trkola A, Moore PL. Vaccinating people living with HIV: a fast track to preventive and therapeutic
495 HIV vaccines. The Lancet Infectious Diseases [Internet]. 23 oct 2023 [cité 9 nov 2023];0(0).
496 Disponible sur: [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(23\)00481-4/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00481-4/fulltext)
497
- 498 11. Wen Y, Bar KJ, Li JZ. Lessons learned from HIV antiretroviral treatment interruption trials. Current
499 Opinion in HIV and AIDS. sept 2018;13(5):416.
- 500 12. Dubé K, Agarwal H, Stockman JK, Auerbach JD, Saucedo JA, Conroy AA, et al. “I Would Absolutely
501 Need to Know That My Partner Is Still Going to be Protected”: Perceptions of HIV Cure-Related
502 Research Among Diverse HIV Serodifferent Couples in the United States. AIDS Research and
503 Human Retroviruses. août 2023;39(8):400-13.

- 504 13. Neergaard R, Jones NL, Roebuck C, Rendle KA, Barbati Z, Peterson B, et al. “I Know That I Was a
505 Part of Making a Difference”: Participant Motivations for Joining a Cure-Directed HIV Trial with an
506 Analytical Treatment Interruption. *AIDS Research and Human Retroviruses*. août
507 2023;39(8):414-21.
- 508 14. Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, et al. Recommendations for
509 analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus
510 meeting. *The Lancet HIV*. 1 avr 2019;6(4):e259-68.
- 511 15. Leal L, Fehér C, Richart V, Torres B, García F. Antiretroviral Therapy Interruption (ATI) in HIV-1
512 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological
513 Response. *Vaccines (Basel)*. 5 août 2020;8(3):442.
- 514 16. Lau JSY, Cromer D, Pinkevych M, Lewin SR, Rasmussen TA, McMahon JH, et al. Balancing
515 Statistical Power and Risk in HIV Cure Clinical Trial Design. *The Journal of Infectious Diseases*. 15
516 juill 2022;226(2):236-45.
- 517 17. Fehér C, Leal L, Plana M, Climent N, Crespo Guardo A, Martínez E, et al. Virological Outcome
518 Measures During Analytical Treatment Interruptions in Chronic HIV-1-Infected Patients. *Open
519 Forum Infectious Diseases*. 1 déc 2019;6(12):ofz485.
- 520 18. Graziani GM, Angel JB. Evaluating the efficacy of therapeutic HIV vaccines through analytical
521 treatment interruptions. *Journal of the International AIDS Society*. 2015;18(1):20497.
- 522 19. Treasure GC, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Para M, et al. Relationship Among Viral
523 Load Outcomes in HIV Treatment Interruption Trials. *J Acquir Immune Defic Syndr*. 1 juill
524 2016;72(3):310-3.
- 525 20. Zheng L, Tierney C, Bosch RJ. Analytical Treatment Interruption in HIV Trials: Statistical and Study
526 Design Considerations. *Curr HIV/AIDS Rep*. 1 oct 2021;18(5):475-82.
- 527 21. Lau JSY, Smith MZ, Lewin SR, McMahon JH. Clinical trials of antiretroviral treatment interruption
528 in HIV-infected individuals. *AIDS*. 1 avr 2019;33(5):773.
- 529 22. Lévy Y, Lacabaratz C, Lhomme E, Wiedemann A, Bauduin C, Fenwick C, et al. A Randomized
530 Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-
531 Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial. *Journal of Virology*. 12 avr
532 2021;95(9):10.1128/jvi.02165-20.
- 533 23. Cobb A, Roberts LK, Palucka AK, Mead H, Montes M, Ranganathan R, et al. Development of a HIV-
534 1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine. *Journal of Immunological
535 Methods*. 28 févr 2011;365(1):27-37.
- 536 24. Lévy Y, Thiébaud R, Montes M, Lacabaratz C, Sloan L, King B, et al. Dendritic cell-based
537 therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of
538 viral load. 2014;9.
- 539 25. Thiébaud R, Hejblum BP, Hocini H, Bonnabau H, Skinner J, Montes M, et al. Gene Expression
540 Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With
541 Dendritic Cells in HIV-Infected Individuals. *Front Immunol*. 1 janv 2019;10:874.

- 542 26. Lévy Y, Thiébaud R, Gougeon ML, Molina JM, Weiss L, Girard PM, et al. Effect of intermittent
543 interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV.
544 AIDS. 27 mars 2012;26(6):711.
- 545 27. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach
546 to Multiple Testing. Journal of the Royal Statistical Society: Series B (Methodological).
547 1995;57(1):289-300.
- 548 28. Alexandre M, Prague M, Thiébaud R. Between-group comparison of area under the curve in
549 clinical trials with censored follow-up: Application to HIV therapeutic vaccines. Stat Methods
550 Med Res. 1 oct 2021;30(9):2130-47.
- 551 29. García F, Climent N, Guardo AC, Gil C, León A, Aufran B, et al. A Dendritic Cell-Based Vaccine
552 Elicits T Cell Responses Associated with Control of HIV-1 Replication. Science Translational
553 Medicine. 2 janv 2013;5(166):166ra2-166ra2.
- 554 30. Peay HL, Rennie S, Cadigan RJ, Gwaltney A, Jupimai T, Phanuphak N, et al. Attitudes About
555 Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy
556 (ART) Resumption Criteria. AIDS Behav. 1 mai 2022;26(5):1504-16.
- 557 31. Protiere C, Arnold M, Fiorentino M, Fressard L, Lelièvre JD, Mimi M, et al. Differences in HIV cure
558 clinical trial preferences of French people living with HIV and physicians in the ANRS-APSEC
559 study: a discrete choice experiment. Journal of the International AIDS Society.
560 2020;23(2):e25443.
- 561 32. Lau JSY, Smith MZ, Allan B, Martinez C, Power J, Lewin SR, et al. Perspectives on Analytical
562 Treatment Interruptions in People Living with HIV and Their Health Care Providers in the
563 Landscape of HIV Cure-Focused Studies. AIDS Res Hum Retroviruses. 1 avr 2020;36(4):260-7.
- 564 33. Dubé K, Agarwal H, Carter WB, Dee L, Taylor J, Roebuck C, et al. Participant experiences using
565 novel home-based blood collection device for viral load testing in HIV cure trials with analytical
566 treatment interruptions. HIV Research & Clinical Practice. 31 déc 2022;23(1):76-90.
- 567

↓ [LIGHT] Prime vaccination: DNA GTU-MultiHIV B IM (1mg) or Placebo

↓ [LIGHT] Boost vaccination: LIPO-5 vaccine or Placebo



↓ [ILIADe] SC IL-2 cycle (6 × 10⁶ IU twice/day 5 days)

↓ [DALIA] Dendritic cell vaccine, loaded with 5 H-popeptides


↑ Plasma HIV RNA load measurements

— Antiretroviral treatment (ART)


⋯ Potential early ART resumption




A




B




LIGHT





ILIAD






DALIA















Table 1 – Definitions of virological criteria analyzed in the study

| Virological criteria | Definition |
|--|--|
| Fixed criteria | |
| Peak VL <i>[in log₁₀ copies/mL]</i> | The maximum VL value during ATI phase. In case of long ATI phase (e.g., in ILIADE trial), an increasing viral dynamics can be observed in some patients after the stabilization of the dynamics and reach higher values than the peak of rebound. In that case, the higher VL value observed before the stabilization was kept. |
| Setpoint <i>[in log₁₀ copies/mL]</i> | The mean value of VL values belonging to the first sliding window with a height of 0.5 log ₁₀ copies/mL, and with a width of at least 4 weeks including at least two consecutive VL values. |
| Time-averaged AUC (nAUC) <i>[in log₁₀ copies/mL]</i> | Area under the viral rebound curve averaged by the duration (in weeks) of ATI phase. |
| Temporal criteria | |
| Time to rebound (TTR) <i>[in weeks]</i> | The time between ART interruption and the first detectable VL value (>40 copies/mL in LIGHT, and >50 copies/mL in ILIADE and DALIA). |
| Slope of viral rebound <i>[in log₁₀ copies/mL/week]</i> | The slope from the last undetectable VL value to the peak VL. |
| Time to peak VL <i>[in weeks]</i> | The time between ART interruption and the peak VL (only for patients with observed peak VL). |
| Time to setpoint <i>[in weeks]</i> | The time between ART interruption and the first VL value belonging to the window defining the setpoint (only for patients with observed setpoint). |
| Time to VL threshold <i>[in weeks]</i> | The time between ART interruption and the first VL value exceeding a specific VL threshold. Four different VL thresholds, commonly used in HIV vaccine trials, were considered: 200, 1 000, 10 000, and 100 000 copies/mL. |

Abbreviations: ATI, Analytical treatment interruption; VL, Viral load; ART, Antiretroviral treatment.

Table 2 – Description of ATI in the three therapeutic vaccine trials.

| | LIGHT (n=87) | | ILIADE (n=129) | | DALIA (n=19) |
|-----------------------------|----------------|----------------|----------------|-------------|--------------|
| | Placebo (n=31) | Vaccine (n=56) | Control (n=57) | IL2 (n=72) | |
| ATI duration (weeks) | | | | | |
| Median [Min-Max] | 12 [4 ; 12] | 12 [2 ; 12] | 48 [0 ; 48] | 48 [0 ; 48] | 28 [8 ; 36] |
| Nb VL measurements | | | | | |
| Median [Min-Max] | 6 [3 ; 6] | 6 [2 ; 6] | 7 [1 ; 7] | 7 [2 ; 7] | 11 [6 ; 13] |
| ATI re-start* | | | | | |
| n (%) | 7 (23) | 11 (20) | 20 (35) | 14 (19) | 3 (16) |

Abbreviations: ATI, Analytical treatment interruption; VL, Viral load; ART, Antiretroviral treatment.

*Evaluation of the number and the percentage of patient who restart their ART before the end of ATI phase, i.e. before predefined ATI duration in LIGHT (12th week) or before time of primary endpoint in ILIADE (48th week) and DALIA (24th week).

Table 3 - Distribution of the different virological criteria estimated in the three therapeutic vaccine trials.

| | | LIGHT (n=87) | | ILIADE (n=129) | | DALIA (n=19) |
|--|------------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| | | Placebo (n=31) | Vaccine (n=56) | Control (n=57) | IL2 (n=72) | |
| Fixed criteria | | | | | | |
| Peak VL <i>log₁₀ cp/mL</i> | N (%) | 31 (100) | 56 (100) | 55 (96) | 72 (100) | 19 (100) |
| | Median [IQR] | 4.97 [4.53 ; 5.74] | 4.92 [4.62 ; 5.34] | 4.94 [4.29 ; 5.05] | 4.68 [4.20 ; 4.99] | 4.94 [4.10 ; 5.18] |
| | P-value ⁽¹⁾ | P = 0.96 | | P = 0.98 | | |
| Setpoint <i>log₁₀ cp/mL</i> | N(%) | 19 (61) | 28 (50) | 48 (84) | 63 (88) | 18 (95) |
| | Median [IQR] | 4.32 [3.97 ; 4.78] | 4.62 [4.42 ; 4.93] | 4.46 [4.00 ; 4.86] | 4.42 [3.96 ; 4.71] | 4.15 [3.92 ; 4.74] |
| | P-value ⁽¹⁾ | P = 0.73 | | P = 0.98 | | |
| nAUC <i>log₁₀ cp/mL</i> | N (%) | 31 (100) | 56 (100) | 55 (95) | 72 (100) | 19 (100) |
| | Median [IQR] | 3.73 [3.28 ; 4.18] | 3.74 [3.25 ; 4.20] | 4.14 [3.75 ; 4.43] | 4.11 [3.63 ; 4.39] | 4.00 [3.68 ; 4.29] |
| | P-value ⁽¹⁾ | P = 0.96 | | P = 0.98 | | |
| Temporal criteria | | | | | | |
| Time to rebound <i>Weeks</i> | N (%) | 30 (97) | 53 (95) | 54 (95) | 71 (99) | 19 (100) |
| | Median [IQR] | 2 [2 ; 4] | 2 [2 ; 4] | 8 [8 ; 8] | 8 [8 ; 8] | 3 [2 ; 6] |
| | P-value ⁽¹⁾ | P = 0.96 | | P = 0.65 | | |
| Slope rebound <i>log₁₀ cp/mL/week</i> | N (%) | 30 (97) | 53 (95) | 54 (94) | 71 (99) | 19 (100) |
| | Median [IQR] | 0.80 [0.56 ; 1.08] | 0.75 [0.59 ; 1.04] | 0.29 [0.16 ; 0.36] | 0.27 [0.18 ; 0.36] | 0.52 [0.36 ; 0.89] |
| | P-value ⁽¹⁾ | P = 0.96 | | P = 0.98 | | |
| Time to peak VL <i>Weeks</i> | N (%) | 31 (100) | 56 (100) | 55 (96) | 72 (100) | 19 (100) |
| | Median [IQR] | 6 [4 ; 6] | 6 [4 ; 6.5] | 8 [8 ; 16] | 8 [8 ; 16] | 8 [4 ; 12] |
| | P-value ⁽¹⁾ | P = 0.96 | | P = 0.98 | | |
| Time to setpoint <i>Weeks</i> | N (%) | 19 (61) | 28 (50) | 48 (84) | 63 (88) | 18 (95) |
| | Median [IQR] | 8 [6 ; 8] | 6 [4 ; 8] | 16 [8 ; 24] | 16 [8 ; 24] | 10 [8 ; 15] |
| | P-value ⁽¹⁾ | P = 0.73 | | P = 0.98 | | |
| Time to 200 cp/mL <i>Weeks</i> | N (%) | 30 (97) | 52 (93) | 54 (95) | 72 (100) | 19 (100) |
| | Median [IQR] | 4 [2 ; 4] | 4 [2 ; 4] | 8 [8 ; 8] | 8 [8 ; 8] | 3 [3 ; 8] |
| | P-value ⁽¹⁾ | P = 0.96 | | P = 0.79 | | |
| Time to 1000 cp/mL <i>Weeks</i> | N (%) | 28 (90) | 52 (93) | 51 (89) | 70 (97) | 18 (95) |
| | Median [IQR] | 4 [2 ; 4] | 4 [2 ; 4] | 8 [8 ; 8] | 8 [8 ; 8] | 4 [3 ; 8] |
| | P-value ⁽¹⁾ | P = 0.96 | | P = 0.55 | | |
| Time to 10000 cp/mL <i>Weeks</i> | N (%) | 27 (87) | 51 (91) | 48 (84) | 59 (82) | 18 (95) |
| | Median [IQR] | 4 [4 ; 6] | 4 [4 ; 6] | 8 [8 ; 8] | 8 [8 ; 8] | 8 [4 ; 12] |
| | P-value ⁽¹⁾ | P = 0.96 | | P = 0.65 | | |
| Time to 1e5 cp/mL <i>Weeks</i> | N (%) | 15 (48) | 27 (48) | 19 (33) | 20 (28) | 10 (53) |
| | Median [IQR] | 4 [4 ; 5] | 6 [4 ; 6] | 16 [8 ; 16] | 16 [8 ; 16] | 8 [5 ; 12] |
| | P-value ⁽¹⁾ | P = 0.73 | | P = 0.98 | | |

Abbreviations: ATI, Analytical treatment interruption ; IQR, Interquartile range; AUC, Area under the curve; VL, Viral load.

“n” indicates the total number of cases, “N” indicates the number of cases with observed endpoints in each group.

⁽¹⁾ P-values of pairwise comparisons (Mann-Whitney U test) in the different trials between therapeutic and control groups.